Lates News

Clinical stage gene editing company Precision BioSciences will release its first quarter 2026 financial report before market open on Tuesday, followed by a conference call at 9:30 am. Analysts are expecting the company to report a loss per share of $0.655 to $0.81 for Q1, with revenue of approximately $4.05 million. It is worth noting that in the past year, the company has exceeded earnings estimates four times, with a success rate of 75%, demonstrating strong cost control capabilities. However, in terms of revenue, the company has only exceeded market expectations once, with a success rate of 25%.